> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Accelerated Approval for Genentech Bladder Cancer Drug
- URL: https://www.fdaweb.com/accelerated-approval-for-genentech-bladder-cancer-drug/
- Published: 2016-05-18T12:00:00.000Z
- Updated: 2026-09-14T21:03:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135705

FDA has granted Genentech accelerated approval for Tecentriq (atezolizumab) for treating people with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months after receiving chemotherapy. Urothelial carcinoma accounts for 90% of all bladder cancer. Approval was based on tumor response rate and duration of response data from a Phase 2 study called IMvigor 210\. Side effects experienced during the trial pneumonitis, hepatitis, colitis, hormone gland problems, neuropathy, meningoencephalitis, eye problems, severe infections and severe infusion reactions, according to the company.